Borovjagin Anton V, Ogle Brenda M, Berry Joel L, Zhang Jianyi
From the Department of Biomedical Engineering, School of Medicine, School of Engineering, The University of Alabama at Birmingham (A.V.B., J.L.B., J.Z.); and Department of Biomedical Engineering, College of Science and Engineering, The University of Minnesota, Minneapolis (B.M.O.).
Circ Res. 2017 Jan 6;120(1):150-165. doi: 10.1161/CIRCRESAHA.116.308538.
Current strategies for engineering cardiovascular cells and tissues have yielded a variety of sophisticated tools for studying disease mechanisms, for development of drug therapies, and for fabrication of tissue equivalents that may have application in future clinical use. These efforts are motivated by the need to extend traditional 2-dimensional (2D) cell culture systems into 3D to more accurately replicate in vivo cell and tissue function of cardiovascular structures. Developments in microscale devices and bioprinted 3D tissues are beginning to supplant traditional 2D cell cultures and preclinical animal studies that have historically been the standard for drug and tissue development. These new approaches lend themselves to patient-specific diagnostics, therapeutics, and tissue regeneration. The emergence of these technologies also carries technical challenges to be met before traditional cell culture and animal testing become obsolete. Successful development and validation of 3D human tissue constructs will provide powerful new paradigms for more cost effective and timely translation of cardiovascular tissue equivalents.
当前用于构建心血管细胞和组织的策略已经产生了各种复杂的工具，用于研究疾病机制、开发药物疗法以及制造可能应用于未来临床的组织等效物。这些努力的动机是需要将传统的二维（2D）细胞培养系统扩展到三维，以更准确地复制心血管结构的体内细胞和组织功能。微尺度装置和生物打印三维组织的发展开始取代传统的二维细胞培养和临床前动物研究，而这些研究在历史上一直是药物和组织开发的标准。这些新方法适用于患者特异性诊断、治疗和组织再生。在传统细胞培养和动物测试过时之前，这些技术的出现也带来了有待解决的技术挑战。三维人体组织构建体的成功开发和验证将为更具成本效益和及时性地转化心血管组织等效物提供强大的新范例。
